

DECLARATION OF CONFORMITY

Manufacturer: **InVivoScribe Technologies, Inc.**
6330 Nancy Ridge Drive, Suite 106
San Diego, California 92121
United States of America

Authorized Representative: **InVivoScribe Technologies, SARL**
Le Forum – Bât B
515 Avenue de la Tramontane
Z1 Athelia IV
13600 La Ciotat, FRANCE
+33 (0)4 42 01 78 10

Family Name: LeukoStrat™

Device Trade Name: **FLT3 Mutation Assay**

Catalog #	Device	Quantity
9-412-0010	FLT3 Mutation Assay for Gel Detection	33 Reactions
9-412-0011	FLT3 Mutation Assay for ABI Fluorescence Detection	33 Reactions
9-412-0012	FLT3 Mutation Assay for Beckman Coulter CE / NAT	33 Reactions
9-412-0020	FLT3 Mutation Assay MegaKit for Gel Detection	330 Reactions
9-412-0021	FLT3 Mutation Assay MegaKit for ABI Fluorescence Detection	330 Reactions
9-412-0022	FLT3 Mutation Assay MegaKit for Beckman Coulter CE / NAT	330 Reactions

I, the undersigned, hereby declare that the *in-vitro* diagnostic medical devices specified above conform to the European Directive 98/79/EC, *In vitro* Diagnostic Medical Device Directive, Annex III.

Date of Validity: _____

Jan 27, 2009

By: _____


Jeffrey E. Miller, PhD
CSO and CEO
InVivoScribe Technologies, Inc.
San Diego, California 92121
USA